Across 15 treated reference arms from nine phase 3 relapsing MS programmes, annualised relapse rates fell from 0.370 (TEMSO) and 0.320 (TOWER) to 0.109–0.140 in BTK inhibitor-era trials, alongside lower prior-year relapse activity; associations were descriptive.
Meta-analysisn = 15 trial arms
Pfeuffer et al. Comparator Event Rates, Baseline Activity, and Operational Selection Pressure in Relapsing Multiple Sclerosis Trials: A Meta-Epidemiological Analysis